Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PNP | P00491 | 13/20 | 1.00 |
| ▸ | HPRT1 | P00492 | 7/20 | 0.83 |
| ▸ | TK1 | P04183 | 1/20 | 0.66 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9701491 | 1.00 | PNP (1.00) | PNPHPRT1TK1 | |
| SCHEMBL9702665 | 1.00 | PNP (1.00) | PNPHPRT1TK1 | |
| SCHEMBL9701538 | 0.99 | PNP (1.00) | PNPHPRT1TK1 | |
| SCHEMBL9515948 | 0.91 | PNP (1.00) | PNPHPRT1TK1 | |
| SCHEMBL9702722 | 0.84 | PNP (0.74) | PNPHPRT1 | |
| SCHEMBL9702718 | 0.83 | PNP (0.76) | PNPHPRT1TK1 | |
| SCHEMBL6397381 | 0.83 | PNP (0.76) | PNPHPRT1TK1 | |
| SCHEMBL8175624 | 0.81 | TK1 (0.97) | PNPHPRT1TK1 | |
| SCHEMBL9053832 | 0.80 | HPRT1 (0.74) | PNPHPRT1 | |
| SCHEMBL24940649 | 0.80 | PNP (0.80) | PNPHPRT1TK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1060182-B1 | NOVEL PRODRUGS FOR PHOSPHORUS-CONTAINING COMPOUNDS | METABASIS THERAPEUTICS INC (US) | 2012-12-19 | — | — | EP | claimed |
| US-7351399-B2 | Prodrugs for phosphorus-containing compounds | METABASIS THERAPEUTICS, INC. (US) | 2008-04-01 | — | — | US | claimed |
| US-20050288240-A1 | Novel-prodrugs for phosphorus-containing compounds | ERION MARK D | 2005-12-29 | — | — | US | claimed |
| US-8664195-B2 | Phosphorus-containing prodrugs | METABASIS THERAPEUTICS, INC. (US) | 2014-03-04 | — | — | US | disclosed |
| EP-1060182-B1 | NOVEL PRODRUGS FOR PHOSPHORUS-CONTAINING COMPOUNDS | METABASIS THERAPEUTICS INC (US) | 2012-12-19 | — | — | EP | disclosed |
| US-20120093729-A1 | NOVEL PHOSPHORUS-CONTAINING PRODRUGS | METABASIS THERAPEUTICS, INC. (US) | 2012-04-19 | — | — | US | disclosed |
| US-8080536-B2 | Phosphorus-containing prodrugs | METABASIS THERAPEUTICS, INC. (US) | 2011-12-20 | — | — | US | disclosed |
| US-20110009356-A1 | NOVEL PHOSPHORUS-CONTAINING PRODRUGS | METABASIS THERAPEUTICS, INC. (US) | 2011-01-13 | — | — | US | disclosed |
| US-7816345-B2 | Phosphorus-containing prodrugs | METABASIS THERAPEUTICS, INC. (US) | 2010-10-19 | — | — | US | disclosed |
| US-20080125605-A1 | Novel Phosphorus-Containing Prodrugs | METABASIS THERAPEUTICS, INC. | 2008-05-29 | — | — | US | disclosed |
| US-7351399-B2 | Prodrugs for phosphorus-containing compounds | METABASIS THERAPEUTICS, INC. (US) | 2008-04-01 | — | — | US | disclosed |
| US-20070249564-A1 | Novel phosphorus-containing prodrugs | METABASIS THERAPEUTICS, INC. (US) | 2007-10-25 | — | — | US | disclosed |
| US-7205404-B1 | Phosphorus-containing prodrugs | METABASIS THERAPEUTICS, INC. (US) | 2007-04-17 | — | — | US | disclosed |
| EP-1724276-A1 | Novel phosphorus-containing prodrugs | Metabasis Therapeutics, Inc. (US) | 2006-11-22 | — | — | EP | disclosed |
| EP-1634886-A2 | Novel phosphorus-containing prodrug | Metabasis Therapeutics, Inc. (US) | 2006-03-15 | — | — | EP | disclosed |
| US-20050288240-A1 | Novel-prodrugs for phosphorus-containing compounds | ERION MARK D | 2005-12-29 | — | — | US | disclosed |
| US-20020052345-A1 | Novel prodrugs for phosphorus-containing compounds | METABASIS THERAPEUTICS, INC. | 2002-05-02 | — | — | US | disclosed |
| US-6312662-B1 | CONVERSION BY HUMAN LIVER MICROSOMES TO MPO3H2 | METABASIS THERAPEUTICS, INC. | 2001-11-06 | — | — | US | disclosed |
| EP-0478292-A1 | Heterocyclic compounds | THE WELLCOME FOUNDATION LIMITED (GB) | 1992-04-01 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080125605-A1 | Novel Phosphorus-Containing Prodrugs | PYGL, ALPI, SLC10A1 | PNP 14/4885HPRT1 227/4885TK1 120/4885 |
| US-20050288240-A1 | Novel-prodrugs for phosphorus-containing compounds | HCRTR2, CYP2R1, SLC22A8 | PNP 599/4885HPRT1 1531/4885TK1 1217/4885 |
| US-20070249564-A1 | Novel phosphorus-containing prodrugs | PYGL, ALPI, SLC10A1 | PNP 14/4885HPRT1 227/4885TK1 120/4885 |
| US-20110009356-A1 | NOVEL PHOSPHORUS-CONTAINING PRODRUGS | PYGL, ALPI, SLC10A1 | PNP 14/4885HPRT1 227/4885TK1 120/4885 |
| US-20020052345-A1 | Novel prodrugs for phosphorus-containing compounds | CCRL2, CCR4, ALK | PNP 159/4885HPRT1 1443/4885TK1 354/4885 |
| US-20120093729-A1 | NOVEL PHOSPHORUS-CONTAINING PRODRUGS | PYGL, ALPI, SLC10A1 | PNP 14/4885HPRT1 227/4885TK1 120/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.